MCAC (Medicare's coverage advisory committee) puts focus on device effectiveness
This article was originally published in Clinica
The executive committee of Medicare's coverage advisory committee (MCAC) has developed recommendations for evaluating whether a medical device or service is effective.
You may also be interested in...
The Italian firm has some talking to do with the US FDA before it can unblind Phase III data on sarizotan, its Rett syndrome therapy which could be "potentially transformative" for Newron.
No device-related warning letters were released by the US FDA the week of 10 December.
Immuno-oncology development trends are revealed through an analysis of deals between cancer drug developers over the past five years.